Achilles Therapeutics has raised £53 million ($70 million) in a Series C financing round, with OrbiMed, Boxer Capital of Tavistock Group, and other healthcare-focused institutional investors joining existing investors. 19 November 2020
Gilead Sciences and development partner Eisai have launched the oral JAK1 blocker Jyseleca (filgotinib maleate) in Japan, for the treatment of rheumatoid arthritis (RA). 18 November 2020
US biotech Five Prime Therapeutics has announced the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share. 17 November 2020
Ophthalmic specialist Spark Therapeutics, a division of Swiss pharma giant Roche, has appointed Michael Retterath as chief strategy officer. 16 November 2020
The US Food and Drug Administration issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Sanofi’s sutimlimab, an investigational monoclonal antibody for the treatment of hemolysis in adults with cold agglutinin disease. 14 November 2020
The European Commission (EC) has approved expanding the indication of Fycompa (perampanel) to include the treatment of children with epilepsy. 13 November 2020
Daiichi Sankyo has reorganized its business structure, with the creation of a new Oncology unit which brings together its American and European oncology businesses. 13 November 2020
China has approved the country's first generic version of now Bristol Myers Squibb company Celgene's Pomalyst (pomalidomide), an immunomodulator treating multiple myeloma. 12 November 2020
US pharma giant Pfizer signed a strategic partnership with Tianjin-based biotech Dynamiker at the China International Import Expo held in Shanghai from November 5 to November 10. 11 November 2020
Privately-held CNS specialist Impel NeuroPharma has submitted a New Drug Application (NDA) for INP104 (dihydroergotamine mesylate) to the US Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adult patients. 10 November 2020
Novavax has appointed Gregory Covino, former group chief financial officer at GlaxoSmithKline’s Tesaro Oncology division, as chief financial officer. 10 November 2020
Brighton, UK-based infectious diseases specialist Destiny Pharma has announced an £11.5 million ($15 million) fundraising round, through the issuance of new shares. 10 November 2020
The biologics subsidiary of Indian generics company Biocon has received a $150 million capital injection from investment bank Goldman Sachs, subject to customary approvals and conditions. 9 November 2020
Japan’s Astellas Pharma has won approval in China for Xtandi (enzalutamide) for people with non-metastatic castration-resistant prostate cancer (nmCRPC), adding to an existing approval in metastatic CRPC. 6 November 2020
British drugmaker AstraZeneca has signed an agreement with the Chinese government in Hainan to expedite the importation of certain drugs. 6 November 2020
Johnson & Johnson’s pharma arm, Janssen, has submitted to the European regulator to broaden the label for Darzalex (daratumumab) subcutaneous (SC) formulation, to include the treatment of people with light chain (AL) amyloidosis. 5 November 2020
US biotech Gilead Sciences has accused two Florida healthcare networks of being involved in a fraudulent scheme to steal millions of dollars from the company’s Advancing Access Medication Assistance Program (MAP) to provide eligible uninsured persons with free medication to help protect them from becoming infected with HIV. 4 November 2020
Medigen Vaccine, a Taipei, Taiwan-based vaccine company, has signed an agreement with Vietnam's National Institute of Hygiene and Epidemiology (NIHE), a division of Vietnam's Ministry of Health, to secure the supply of 3 million to 10 million COVID-19 vaccine doses to Vietnam in 2021. 4 November 2020
Belgian companies Novasep and Handl Therapeutics have signed an agreement for the development and manufacturing of an adeno associated virus (AAV)-based gene therapy drug candidate for the treatment of neurodegenerative diseases. 2 November 2020
Minaris Regenerative Medicine, a contract development and manufacturing organization (CDMO) focused on cell and gene therapies, is expanding its facilities in Europe and Asia. 2 November 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024